Design of a Thomson scattering diagnostic for the SMall Aspect Ratio Tokamak (SMART).

We describe the design of a Thomson scattering (TS) diagnostic to be used on the SMall Aspect Ratio Tokamak (SMART). SMART is a spherical tokamak being commissioned in Spain that aims to explore positive triangularity and negative triangularity plasma scenarios at a low aspect ratio. The SMART TS diagnostic is designed to operate at high spatial resolution, 6 mm scattering length in the low-field side and 9 mm in the high-field side regions, and a wide dynamic range, electron temperature from 1 eV to 1 keV and density from 5×1018m-3 to 1×1020m-3, to resolve large gradients formed at the plasma edge and in the scrape-off layer (SOL) under different triangularities and low aspect ratios.

Low-dose sufentanil does not affect tolerance to LBNP-induced central hypovolemia or blood pressure responses during a cold pressor test.

Hemorrhage is a leading cause of death in the prehospital setting. Since trauma-induced pain often accompanies a hemorrhagic insult, the administered pain medication must not interfere with critical autonomic regulation of arterial blood pressure and vital organ perfusion. The purpose of this study was to test two unrelated hypotheses: ) sublingual sufentanil (Dsuvia) impairs tolerance to progressive central hypovolemia and ) sublingual sufentanil attenuates pain sensation and the accompanying cardiovascular responses to a noxious stimulus.

Synthesis, Catalytic GPx-like Activity, and SET Reactions of Conformationally Constrained 2,7-Dialkoxy-Substituted Naphthalene-1,8-diselenides.

Several 2,7-dialkoxy-substituted naphthalene-1,8-diselenides were prepared and tested for catalytic antioxidant activity in an NMR-based assay employing the reduction of hydrogen peroxide with stoichiometric amounts of benzyl thiol. Acidic conditions enhanced their catalytic activity, whereas basic conditions suppressed it. The highest activity was observed with a 2,7-bis(triethyleneglycol) derivative.

Molnupiravir for the treatment of COVID-19.

Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. NTP inhibits viral polymerase by acting as an alternative substrate.